1. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509. doi:10.1016/S1470-2045(15)00007-8
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. n/a(n/a). doi:https://doi.org/10.3322/caac.21660
3. Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med. 2016;67:91-101. doi:10.1146/annurev-med-051914-021907
4. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(8):1179-1186. doi:10.1093/annonc/mdh308
5. Poeta ML, Manola J, Goldwasser MA, et al. TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2007;357(25):2552-2561. doi:10.1056/NEJMoa073770
6. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(1):290-300. doi:10.1158/1078-0432.CCR-11-2260
7. Kumar M, Molkentine D, Molkentine J, et al. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021;12(1):6340. doi:10.1038/s41467-021-26570-8
8. Uzunparmak B, Gao M, Lindemann A, et al. Caspase 8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic induced necroptosis. JCI Insight. Published online 2020. doi:10.1172/jci.insight.139837
9. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-595. doi:10.1182/blood-2009-02-206870
10. Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11-17. doi:10.1016/j.semradonc.2014.07.005
11. Miyauchi S, Kim SS, Pang J, et al. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(14):4211-4223. doi:10.1158/1078-0432.CCR-18-0871
12. Skinner HD, Giri U, Yang LP, et al. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(11):2713-2722. doi:10.1158/1078-0432.CCR-16-2586
13. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184. doi:10.1186/s40425-019-0662-5
14. Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450-462. doi:10.1016/S1470-2045(20)30737-3
15. Kumar M, Molkentine D, Molkentine J, et al. CREBBP/EP300 mutation is associated with poor outcome in HNSCC and targetable with synthetic cytotoxicity. bioRxiv. Published online January 1, 2020:2020.04.10.028217. doi:10.1101/2020.04.10.028217
16. Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401-404. doi:10.1158/2159-8290.CD-12-0095
17. Skinner HD, Giri U, Yang L, et al. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016;22(18):4643-4650. doi:10.1158/1078-0432.CCR-15-2785
18. Zhang J, Bajari R, Andric D, et al. The International Cancer Genome Consortium Data Portal. Nat Biotechnol. 2019;37(4):367-369. doi:10.1038/s41587-019-0055-9
19. Maitra A, Biswas NK, Amin K, et al. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun. 2013;4(1):2873. doi:10.1038/ncomms3873
20. Huang C, Chen L, Savage SR, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39(3):361-379.e16. doi:10.1016/j.ccell.2020.12.007
21. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
22. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218. doi:10.1038/nature12213
23. Chakravarty D, Gao J, Phillips S, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;(1):1-16. doi:10.1200/PO.17.00011
24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x
25. Wondergem NE, Nauta IH, Muijlwijk T, Leemans CR, van de Ven R. The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites. Curr Oncol Rep. 2020;22(8):81. doi:10.1007/s11912-020-00938-3
26. Spector ME, Bellile E, Amlani L, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Neck Surg. 2019;145(11):1012-1019. doi:10.1001/jamaoto.2019.2427
27. Mandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829. doi:10.1172/jci.insight.89829
28. Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol. 2018;18(2):121-133. doi:10.1038/nri.2017.118
29. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 2008;68(20):8456-8464. doi:10.1158/0008-5472.CAN-08-2213
30. Lorvik KB, Hammarström C, Fauskanger M, et al. Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response. Cancer Res. 2016;76(23):6864-6876. doi:10.1158/0008-5472.CAN-16-1219
31. Muraille E, Leo O, Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol. 2014;5:603. doi:10.3389/fimmu.2014.00603
32. Corrigan CJ, Wang W, Meng Q, et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A. 2011;108(4):1579-1584. doi:10.1073/pnas.1014241108
33. Grotz TE, Jakub JW, Mansfield AS, et al. Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology. 2015;4(8):e1026504. doi:10.1080/2162402X.2015.1026504
34. Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother Hagerstown Md 1997. 2012;35(2):169-178. doi:10.1097/CJI.0b013e318247a4e7
35. Sun W, Li WJ, Fu QL, et al. Functionally distinct subsets of CD4+ regulatory T cells in patients with laryngeal squamous cell carcinoma are indicative of immune deregulation and disease progression. Oncol Rep. 2015;33(1):354-362. doi:10.3892/or.2014.3553
36. Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27(1):31-39. doi:10.1002/hon.878
37. Rui X, Shao S, Wang L, Leng J. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. BMC Cancer. 2019;19(1):1179. doi:10.1186/s12885-019-6391-9
38. Qi X, Gurung P, Malireddi RKS, et al. Critical role of caspase-8-mediated IL-1 signaling in promoting Th2 responses during asthma pathogenesis. Mucosal Immunol. 2017;10(1):128-138. doi:10.1038/mi.2016.25
39. Ando M, Kawazu M, Ueno T, et al. Cancer-associated missense mutations of caspase-8 activate nuclear factor-κB signaling. Cancer Sci. 2013;104(8):1002-1008. doi:10.1111/cas.12191
40. Yang Y, Yoo HM, Choi I, Pyun KH, Byun SM, Ha H. Interleukin 4-induced proliferation in normal human keratinocytes is associated with c-myc gene expression and inhibited by genistein. J Invest Dermatol. 1996;107(3):367-372. doi:10.1111/1523-1747.ep12363346
41. Ciszewski WM, Wagner W, Kania KD, Dastych J. Interleukin-4 enhances PARP-dependent DNA repair activity in vitro. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2014;34(9):734-740. doi:10.1089/jir.2014.0029